Harvard Pilgrim Health Care announced that it has signed a value-based contract with Eli Lilly for its type 2 diabetes drug, Trulicity. The arrangement gives Trulicity preferred status on Harvard Pilgrim’s formulary and means that Harvard Pilgrim will pay a lower net cost to Eli Lilly if fewer of its members reach a preferred endpoint (HbA1c less than 8%) as compared to individuals taking other GLP-1 receptor agonists, and a higher net cost if patients taking Trulicity do better than patients taking competing drugs.

View Harvard Pilgrim Health Care press release